Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza virus split vaccine (low protein, low ovalbumin)
- Development stage
- Approved
- Lead developer
- Anhui Zhifei Longcom Biopharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The influenza virus split vaccine (low protein, low ovalbumin) is a seasonal influenza vaccine developed by Zhifei (Chongqing Zhifei Biological Products Co., Ltd.). It is an inactivated split virion vaccine produced by inoculating chicken embryos with WHO-recommended influenza virus strains, followed by culture, inactivation, and purification. This specific formulation is characterized by its low protein content, low ovalbumin (egg albumin) residue, and low endotoxin levels, which is designed to provide a safer profile and reduce the risk of allergic reactions associated with egg-based production. The vaccine works by eliciting strain-specific neutralizing antibody responses against the hemagglutinin and neuraminidase antigens of the seasonal influenza virus strains.
- Other names
- 流感病毒裂解疫苗 (低蛋白、低卵白蛋白)influenza virus split vaccine-IPS/ZhifeiZhifei influenza virus split vaccine
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on influenza virus split vaccine (low protein, low ovalbumin).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza virus split vaccine (low protein, low ovalbumin).